Skip to content

Depression: all studies

Page 847 of 1,034: studies 8,461 to 8,470 of 10,336, newest first. Back to the depression overview

Research

Mindfulness‐based stress reduction for psychological distress among nurses: A systematic review

Journal of Clinical Nursing July 3, 2019 Sajed Faisal Ghawadra, Khatijah Lim Abdullah, Wan Yuen Choo et al. 163 citations

AIMS AND OBJECTIVES: To explore the studies that used interventions based on the Mindfulness-Based Stress Reduction (MBSR) for decreasing psychological distress among nurses. BACKGROUND: Because of the demanding nature of their work, nurses often have significantly high levels of stress, anxiety and depression. MBSR has been reported to be an effective intervention to decrease psychological...

DOI: 10.1111/jocn.14987 (opens in new tab) Anxiety Mindfulness-based stress reduction Psychological intervention Burnout +6

Greater Anteroposterior Default Mode Network Functional Connectivity in Long-Term Elderly Yoga Practitioners

Frontiers in Aging Neuroscience July 2, 2019 Danilo Forghieri Santaella, Joana Bisol Balardin, Rui F. Afonso et al. 37 citations

Large-scale brain networks exhibit changes in functional connectivity during the aging process. Recent literature data suggests that Yoga and other contemplative practices may revert, at least in part, some of the aging effects in brain functional connectivity, including of the Default Mode Network (DMN). The aim of this cross-sectional investigation was to compare resting-state functional...

Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy.

Journal of Molecular Neuroscience July 2019 Cheng Jiang, Wei-Jye Lin, Stephen R Salton

Members of the neurotrophin family and in particular brain-derived neurotrophic factor (BDNF) regulate the response to rapid- and slow-acting chemical antidepressants and voluntary exercise. Recent work suggests that rapid-acting antidepressants that modulate N-methyl-D-aspartate receptor (NMDA-R) signaling (e.g., ketamine and GLYX-13) require expression of VGF (non-acronymic), the...

Salvindolin elicits opioid system-mediated antinociceptive and antidepressant-like activities.

Journal of Psychopharmacology July 2019 Adam W Keasling, Pankaj Pandey, Robert J Doerksen et al.

Salvinorin A is known as a highly selective kappa opioid receptor agonist with antinociceptive but mostly pro-depressive effects. In this article, we present its new semisynthetic analog with preferential mu opioid affinity, and promising antinociceptive, as well as antidepressant-like activities. Competitive binding studies were performed for salvindolin with kappa opioid and mu opioid. The...

Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice.

Journal of Pharmacology and Experimental Therapeutics July 1, 2019 Eduardo R Butelman, Bryan D McElroy, Thomas E Prisinzano et al.

The kappa (κ) opioid receptor/dynorphin system modulates depression-like states and anhedonia, as well adaptations to stress and exposure to drugs of abuse. Several relatively short-acting small molecule κ-receptor antagonists have been synthesized, and their behavioral profile has been examined under some conditions. The hypothesis of this study is that pharmacological manipulations of the...

Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.

Pharmacology & Therapeutics July 1, 2019 T. H. Pham, Alain M. Gardier 190 citations

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays a fast antidepressant activity in treatment-resistant depression and in rodent models of anxiety/depression. A large body of evidence concerning the cellular and molecular mechanisms underlying its fast antidepressant-like activity comes from animal studies. Although structural remodeling of...

The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion

Journal of Psychedelic Studies July 1, 2019 Jamilah R. George, Timothy I. Michaels, Jae Sevelius et al. 222 citations

In recent years, the study of psychedelic science has resurfaced as scientists and therapists are again exploring its potential to treat an array of psychiatric conditions, such as depression, post-traumatic stress disorder, and addiction. The scientific progress and clinical promise of this movement owes much of its success to the history of indigenous healing practices; yet the work of...

DOI: 10.1556/2054.2019.015 (opens in new tab) Full text (opens in new tab) Indigenous Mainstream Ethnic group Inclusion mineral +8

Psychedelic drugs—a new era in psychiatry?

Dialogues in Clinical Neuroscience June 30, 2019 David Nutt 131 citations

This article covers the renaissance of classical psychedelic drugs such as psilocybin and LSD plus 3,4-methylene dioxymethamphetamine (MDMA-ecstasy) in psychiatric research. These drugs were used quite extensively before they became prohibited. This ban had little impact on recreational use, but effectively stopped research and clinical treatments, which up to that point had looked very...

The Effects of Different Stages of Mindfulness Meditation Training on Emotion Regulation

Frontiers in Human Neuroscience June 27, 2019 Qin Zhang, Zheng Wang, Xinqiang Wang et al.

This study examined mood enhancement effects from 4-week focusing attention (FA) meditation and 4-week open monitoring (OM) meditation in an 8-week mindfulness training program designed for ordinary individuals. Forty participants were randomly assigned to a training group or a control group. All participants were asked to perform cognitive tasks and subjective scale tests at three time points...

DOI: 10.3389/fnhum.2019.00208 (opens in new tab) Full text (opens in new tab) Mindfulness meditation Focusing attention Open monitoring Emotion regulation +1

Interaction of Sex and Age on the Dissociative Effects of Ketamine Action in Young Healthy Participants

Frontiers in Neuroscience June 18, 2019 Birgit Derntl, J. Hornung, Z. Sen et al.

Ketamine is a drug that reduces depressive and elicits schizophrenia-like symptoms in humans. However, it is largely unexplored whether women and men differ with respect to ketamine-action and whether age contributes to drug-effects. In this study we assessed dissociative symptoms via the Clinician Administered Dissociative States Scale (CADSS) in a total of 69 healthy subjects aged between 18...